A&O advises Apax Partners and Neuraxpharm on Buccolam acquisition
Allen & Overy has advised Apax Partners and its portfolio company Neuraxpharm on the acquisition of Buccolam assets from Takeda
Apax Partners and its portfolio company Neuraxpharm Group, a leading European speciality pharmaceutical company focused on the central nervous system (CNS), have acquired the assets and rights related to prescription brand Buccolam from Takeda Pharmaceutical Company Limited, a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, in a multinational asset deal. The transaction is expected to close by the end of 2020.
Buccolam is a leading treatment for prolonged, acute, convulsive seizures (PACS) in infants, children and adolescents, with an extensive customer base across 18 countries in Europe and Israel.
Allen & Overy’s cross border experience within the healthcare and pharmaceuticals space played an important role in this transaction, which will bring a critical and highly effective treatment to new markets. The U.S. Corporate and M&A practices worked alongside colleagues in the UK, Spain and Germany to address the cross-border complexities of this transaction.
The Allen & Overy team advising Neuraxpharm Group was led by New York office M&A partner Paul Burns (pictured left), supported by teams from London, Madrid, Munich, Frankfurt and Hamburg. From the Madrid office, the support was provided by associate Marta Guardiola (pictured right).